SARS-CoV-2-Infektion und interstitielle Lungenerkrankungen – Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Zusammenfassung

Die SARS-CoV-2-Pandemie hat in erheblichem Umfang die Diagnostik und Therapie interstitieller Lungenerkrankungen (ILD) beeinflusst. Insbesondere in der Frühphase der Pandemie und unter dem Einfluss der Delta-Variante ist es zu zahlreichen COVID-19-Pneumonien gekommen, in deren Gefolge sich bestehende interstitielle Lungenerkrankungen verschlechtert haben, neue entstanden sind oder entdeckt wurden. Den Einfluss einer SARS-CoV-2-Infektion – mit oder Viruspneumonie – auf vorbestehende ILD sowie die weitere Entwicklung neu entstandener pulmonaler Infiltrate und Konsolidierungen abzuschätzen, zu diagnostizieren und angemessen zu behandeln stellt eine nahezu tägliche Herausforderung in den interdisziplinären ILD-Boards dar. Mit diesem Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungstherapie e.V. (DGP) werden auf Basis des aktuellen Wissensstandes Antworten auf die wichtigsten Fragestellungen gegeben.

Abstract

The SARS-CoV-2 pandemic had a tremendous impact on diagnosis and treatment of interstitial lung diseases (ILD). Especially in the early phase of the pandemic, when the delta variant was prevailling, a huge number of viral pneumonias were observed, which worsened pre-existing, triggered de novo occurence or discovery of previously subclincal interstitial lung diseases. The effect of SARS-CoV-2 infection – without or with accompanying viral pneumonia – on the further development of pre-existing ILD as well of new pulmonary inflitrates and consolidiations is difficult to predict and poses a daily challenge to interdisciplinary ILD boards. This position paper of the German Respiratory Society (DGP e.V.) provides answers to the most pressing questions based on current knowledge.

Schlüsselwörter

COVID-19 - SARS-CoV-2 - interstitielle Lungenerkrankungen - Lungenfibrose - Diagnostik und Therapie

Keywords

COVID-19 - SARS-CoV-2 - interstitial lung disease - pulmonary fibrosis - diagnosis and therapy

Publication History

Received: 07 December 2022

Accepted after revision: 02 January 2023

Article published online:
14 March 2023

• Literatur

• 1 WHO Stand 10/2022. Accessed December 23, 2022 at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
• 2 Koczulla AR, Ankermann T, Behrends U. et al. S1-Leitlinie Post-COVID/Long-COVID [S1 Guideline Post-COVID/Long-COVID]. Pneumologie 2021; 75: 869-900 DOI: 10.1055/a-1551-9734.
• 3 Huang C, Huang L, Wang Y. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-232 DOI: 10.1016/S0140-6736(20)32656-8.
• 4 Drake TM, Docherty AB, Harrison EM. et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 2020; 202: 1656-1665 DOI: 10.1164/rccm.202007-2794OC.
• 5 Xie L, Liu Y, Xiao Y. et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest 2005; 127: 2119-24 DOI: 10.1378/chest.127.6.2119. (PMID: 15947329)
• 6 Zhang P, Li J, Liu H. et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res 2020; 8: 8 DOI: 10.1038/s41413-020-0084-5. Erratum in: Bone Res 2020; 8: 34
• 7 Choi WS, Kang CI, Kim Y. et al. Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother 2016; 48: 118-26 DOI: 10.3947/ic.2016.48.2.118. (PMID: 27433382)
• 8 Wu X, Liu X, Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021; 9: 747-754 DOI: 10.1016/S2213-2600(21)00174-0. (PMID: 33964245)
• 9 Chen Y, Ding C, Yu L. et al. One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection. BMC Med 2021; 19: 191 DOI: 10.1186/s12916-021-02056-8. (PMID: 34365975)
• 10 Faverio P, Luppi F, Rebora P. et al. One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study. Respir Res 2022; 23: 65 DOI: 10.1186/s12931-022-01994-y. (PMID: 35313890)
• 11 Wolter N, Jassat W, Walaza S. et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399: 437-446 DOI: 10.1016/S0140-6736(22)00017-4. (PMID: 35065011)
• 12 Collard HR, Ryerson CJ, Corte TJ. et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016; 194: 265-75 DOI: 10.1164/rccm.201604-0801CI. (PMID: 27299520)
• 13 Goto Y, Sakamoto K, Fukihara J. et al. COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review. Front Med (Lausanne) 2022; 9: 815924 DOI: 10.3389/fmed.2022.815924.
• 14 Lee H, Choi H, Yang B. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021; 58: 2004125 DOI: 10.1183/13993003.04125-2020. (PMID: 33888524)
• 15 Esposito AJ, Menon AA, Ghosh AJ. et al. Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med 2020; 202: 1710-1713 DOI: 10.1164/rccm.202006-2441LE.
• 16 Verma A, Minnier J, Wan ES. et al. A MUC5B Gene Polymorphism, rs35705950-T Confers Protective Effects Against COVID-19 Hospitalization but not Severe Disease or Mortality. Am J Respir Crit Care Med 2022; DOI: 10.1164/rccm.202109-2166OC. (PMID: 35771531)
• 17 Froidure A, Mahieu M, Hoton D. et al. Short telomeres increase the risk of severe COVID-19. Aging (Albany NY) 2020; 12: 19911-19922 DOI: 10.18632/aging.104097. (PMID: 33104521)
• 18 McGroder CF, Zhang D, Choudhury MA. et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax 2021; 76: 1242-1245 DOI: 10.1136/thoraxjnl-2021-217031.
• 19 Gallay L, Uzunhan Y, Borie R. et al. Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. Am J Respir Crit Care Med 2021; 203: 245-249 DOI: 10.1164/rccm.202007-2638LE.
• 20 Aveyard P, Gao M, Lindson N. et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study. Lancet Respir Med 2021; 9: 909-923 DOI: 10.1016/S2213-2600(21)00095-3.
• 21 Valenzuela C, Waterer G, Raghu G. Interstitial lung disease before and after COVID-19: a double threat?. Eur Respir J 2021; 58: 2101956 DOI: 10.1183/13993003.01956-2021. (PMID: 34857587)
• 22 Mackintosh JA, Lipman M, Lowe DM. et al. Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. Lancet Respir Med 2021; 9: 947-949 DOI: 10.1016/S2213-2600(21)00326-X.
• 23 Myall KJ, Martinovic JL, West A. How COVID-19 interacts with interstitial lung disease. Breathe (Sheff) 2022; 18: 210158 DOI: 10.1183/20734735.0158-2021. (PMID: 35284020)
• 24 Venkatesan P. NICE guideline on long COVID. Lancet Respir Med 2021; 9: 129 DOI: 10.1016/S2213-2600(21)00031-X. (PMID: 33453162)
• 25 Covid-19-Verdacht. Accessed October 20, 2022 at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Massnahmen_Verdachtsfall
• 26 Saha BK, Saha S, Chong WH. et al. Indications, Clinical Utility, and Safety of Bronchoscopy in COVID-19. Respir Care 2022; 67: 241-251 DOI: 10.4187/respcare.09405. (PMID: 34848547)
• 27 Roden AC, Boland JM, Johnson TF. et al. Late Complications of COVID-19. Arch Pathol Lab Med 2022; 146: 791-804 DOI: 10.5858/arpa.2021-0519-SA. (PMID: 35319744)
• 28 Chang J, Swenson KE, Sung A. et al. Coronavirus Disease 2019 Test Correlation Between Nasopharyngeal Swab and BAL in Asymptomatic Patients. Chest 2021; 159: 2488-2490 DOI: 10.1016/j.chest.2020.11.006.
• 29 Lee H, Choi H, Yang B. et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021; 58: 2004125 DOI: 10.1183/13993003.04125-2020. (PMID: 33888524)
• 30 Covid-19: Manifestationen, Komplikationen, Langzeitfolgen. Accessed November 26, 2021 at: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html
• 31 Omote N, Kanemitsu Y, Inoue T. et al. Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19. Intern Med 2022; 61: 233-236 DOI: 10.2169/internalmedicine.8163-21.
• 32 Darwiche K, Ross B, Gesierich W. et al. Empfehlungen zur Durchführung einer Bronchoskopie in Zeiten der COVID-19-Pandemie: Update 12/2020 [Recommendations for Performing Bronchoscopy in Times of the COVID-19 Pandemic – Update 12/2020]. Pneumologie 2021; 75: 187-190 DOI: 10.1055/a-1320-8250.
• 33 Ravaglia C, Doglioni C, Chilosi M. et al. Clinical, radiological and pathological findings in patients with persistent lung disease following SARS-CoV-2 infection. Eur Respir J 2022; 60: 2102411 DOI: 10.1183/13993003.02411-2021.
• 34 Livrieri F, Ghidoni G, Piro R. et al. May 2020: Is It Always COVID-19 No Matter What?. Int Med Case Rep J 2020; 13: 563-567 DOI: 10.2147/IMCRJ.S277474.
• 35 Gagiannis D, Steinestel J, Hackenbroch C. et al. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD). Front Immunol 2020; 11: 587517 DOI: 10.3389/fimmu.2020.587517.
• 36 Zeng Q, Tang C, Deng L. et al. Differential Diagnosis of COVID-19 Pneumonia in Cancer Patients Received Radiotherapy. Int J Med Sci 2020; 17: 2561-2569 DOI: 10.7150/ijms.46133. (PMID: 33029098)
• 37 Konopka KE, Perry W, Huang T. et al. Usual Interstitial Pneumonia is the Most Common Finding in Surgical Lung Biopsies from Patients with Persistent Interstitial Lung Disease Following Infection with SARS-CoV-2. EClinicalMedicine 2021; 42: 101209 DOI: 10.1016/j.eclinm.2021.101209.
• 38 Behr J, Günther A, Bonella F. et al. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose [German Guideline for Idiopathic Pulmonary Fibrosis]. Pneumologie 2020; 74: 263-293 DOI: 10.1055/a-1120-3531. Erratum in: Pneumologie. 2020;74:e1-e2
• 39 Sonnweber T, Sahanic S, Pizzini A. et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J 2021; 57: 2003481 DOI: 10.1183/13993003.03481-2020. (PMID: 33303539)
• 40 Antoniou KM, Vasarmidi E, Russell AM. et al. European Respiratory Society statement on long COVID follow-up. Eur Respir J 2022; 60: 2102174 DOI: 10.1183/13993003.02174-2021. (PMID: 35144991)
• 41 Culebras M, Loor K, Sansano I. et al. Histological Findings in Transbronchial Cryobiopsies Obtained From Patients After COVID-19. Chest 2022; 161: 647-650 DOI: 10.1016/j.chest.2021.09.016.
• 42 Vogel-Claussen J, Ley-Zaporozhan J, Agarwal P. et al. Recommendations of the Thoracic Imaging Section of the German Radiological Society for clinical application of chest imaging and structured CT reporting in the COVID-19 pandemic. Rofo 2020; 192: 633-640 DOI: 10.1055/a-1174-8378. (PMID: 32455442)
• 43 Protokollempfehlungen der AG DRauE zur Durchführung von Low-Dose-Volumen-HRCT-Untersuchungen der Lunge. Accessed January 20, 2023 at: https://www.ag-draue.drg.de/de-DE/3545/protokollempfehlungen-der-ag-draue-zurdurchfuehrung-von-low-dose-volumen-hrct-untersuchungen-derlunge/
• 44 Lax SF, Skok K, Zechner P. et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med 2020; 173: 350-361 DOI: 10.7326/M20-2566.
• 45 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120-128 DOI: 10.1056/NEJMoa2015432. (PMID: 32437596)
• 46 Calabrese F, Pezzuto F, Fortarezza F. et al. Machine learning-based analysis of alveolar and vascular injury in SARS-CoV-2 acute respiratory failure. J Pathol 2021; 254: 173-184 DOI: 10.1002/path.5653. (PMID: 33626204)
• 47 Gao Y, Chen Y, Liu M. et al. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect 2020; 81: e93-e95 DOI: 10.1016/j.jinf.2020.05.017. (PMID: 32417309)
• 48 Fonseca M, Summer R, Roman J. Acute Exacerbation of Interstitial Lung Disease as a Sequela of COVID-19 Pneumonia. Am J Med Sci 2021; 361: 126-129 DOI: 10.1016/j.amjms.2020.08.017. (PMID: 32912600)
• 49 Neue Empfehlungen zu COVID-19 und Rheuma (dgrh.de). Accessed October 28, 2022 at: https://dgrh.de/Start/Wissenschaft/Forschung/COVID-19/COVID-19---Rheuma--Publikationen-der-DGRH/2022/Neue-Empfehlungen-zu-COVID-19-und-Rheuma.html
• 50 Park JY, Kim JH, Lee IJ. et al. COVID-19 vaccine-related interstitial lung disease: a case study. Thorax 2022; 77: 102-104 DOI: 10.1136/thoraxjnl-2021-217609. (PMID: 34362838)
• 51 Ghincea A, Ryu C, Herzog EL. An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report. Chest 2022; 161: e71-e73 DOI: 10.1016/j.chest.2021.07.2160. (PMID: 35131075)
• 52 STAKOB: Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19, RKI-Stellungnahmen – STAKOB: Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. Accessed April 06, 2021 at: https://www.rki.de/DE/Content/Kommissionen/Stakob/Stellungnahmen/Stellungnahme-Covid-19_Therapie_Diagnose.html
• 53 Pogatchnik BP, Swenson KE, Sharifi H. et al. Radiology-Pathology Correlation Demonstrating Organizing Pneumonia in a Patient Who Recovered from COVID-19. Am J Respir Crit Care Med 2020; 202: 598-599 DOI: 10.1164/rccm.202004-1278IM.
• 54 Myall KJ, Mukherjee B, Castanheira AM. et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. Ann Am Thorac Soc 2021; 18: 799-806 DOI: 10.1513/AnnalsATS.202008-1002OC. (PMID: 33433263)
• 55 Dhooria S, Chaudhary S, Sehgal IS. et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J 2022; 59: 2102930 DOI: 10.1183/13993003.02930-2021.
• 56 Marwah V, Choudhary R, Malik V. et al. Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series. Adv Respir Med 2021; 89: 589-596 DOI: 10.5603/ARM.a2021.0113. (PMID: 34966994)
• 57 Umemura Y, Mitsuyama Y, Minami K. et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis 2021; 108: 454-460 DOI: 10.1016/j.ijid.2021.05.055. (PMID: 34048887)
• 58 Acat M, Yildiz Gulhan P. et al. Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. Int J Clin Pract 2021; 75: e14961 DOI: 10.1111/ijcp.14961.
• 59 Flaherty KR, Wells AU. Cottin V INBUILD Trial Investigators. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381: 1718-1727 DOI: 10.1056/NEJMoa1908681.
• 60 Behr J, Prasse A, Kreuter M. et al. RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476-486 DOI: 10.1016/S2213-2600(20)30554-3.
• 61 Roach A, Chikwe J, Catarino P. et al. Lung Transplantation for Covid-19-Related Respiratory Failure in the United States. N Engl J Med 2022; 386: 1187-1188 DOI: 10.1056/NEJMc2117024. (PMID: 35081299)
• 62 Kurihara C, Manerikar A, Querrey M. et al. Clinical Characteristics and Outcomes of Patients With COVID-19-Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant. JAMA 2022; 327: 652-661 DOI: 10.1001/jama.2022.0204.
• 63 Mohanka MR, Joerns J, Lawrence A. et al. ECMO Long Haulers: A Distinct Phenotype of COVID-19-Associated ARDS With Implications for Lung Transplant Candidacy. Transplantation 2022; 106: e202-e211 DOI: 10.1097/TP.0000000000004052.
• 64 Bermudez CA, Crespo MM. The Case for Prolonged ECMO for COVID-19 ARDS as a Bridge to Recovery or Lung Transplantation. Transplantation 2022; 106: e198-e199 DOI: 10.1097/TP.0000000000004063. (PMID: 35135969)
• 65 Schwarz S, Lang C, Harlander M. et al. Gamma-glutamyltransferase is a strong predictor of secondary sclerosing cholangitis after lung transplantation for COVID-19 ARDS. J Heart Lung Transplant 2022; 41: 1501-1510 DOI: 10.1016/j.healun.2022.06.020. (PMID: 35907758)
• 66 Ackermann M, Tafforeau P, Wagner WL. et al. The Bronchial Circulation in COVID-19 Pneumonia. Am J Respir Crit Care Med 2022; 205: 121-125 DOI: 10.1164/rccm.202103-0594IM. (PMID: 34734553)